Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors in Phase III NSCLC Trial | #genentech # Divarasib # KRAS G12C inhibitors # Non-small cell lung cancer # NSCLC treatment # Lung cancer treatment # Phase III clinical trial # Targeted cancer therapy # Oncology news # Precision oncology # Advanced NSCLC